📌 Key Takeaways
- Japan’s amended Regenerative Medicine Safety Act took effect on May 31, 2025 —
but exosomes remain outside its scope, classified as “not cells themselves.” - As of 2023, 669 clinics across Japan offer exosome treatments,
primarily for anti-aging, hair restoration, and fatigue recovery —
with no mandatory quality or purity standards. - The U.S. FDA has stated that zero exosome products hold approval for cosmetic use,
and administering unapproved biologics to patients violates federal law. - Japan’s Ministry of Health had indicated regulations would be in place “by 2026,”
but as of June 2026, no specific regulatory framework has been published.
“Is it safe to get an exosome injection?”
Ask that question at a clinic consultation,
and you may not get a clear answer.
That ambiguity isn’t necessarily the clinic’s fault.
It reflects a structural gap in Japan’s regulatory system.
One year after the amended Regenerative Medicine Safety Act took effect on May 31, 2025,
the question remains: what has changed — and what hasn’t?
INDEX
What the Amended Regenerative Medicine Act Actually Changed
📅 Timeline: Japan’s Regenerative Medicine Law and Exosomes
Japan promulgates the amended Regenerative Medicine Safety Act.
A supplementary provision states that “legal measures regarding therapies using cell secretions
shall be taken within two years of enforcement.”
Japan’s Pharmaceutical Affairs Bureau issues a notice on “Monitoring and Guidance Regarding Exosome Reagents,”
signaling intent to crack down on exosome products marketed with drug-like claims
as unapproved, unlicensed pharmaceuticals.
The Medical Policy Bureau issues a separate notice on “Medical Practices Using Stem Cell Conditioned Media and Exosomes,”
requiring clinics offering these treatments to follow guidance from the Japanese Society for Regenerative Medicine.
A patient dies of cardiac arrest during an autologous adipose-derived stem cell IV infusion
at a private regenerative medicine clinic.
Japan’s MHLW issues an emergency business suspension order.
(A stem cell case — but a stark warning for the broader industry.)
Amended Regenerative Medicine Safety Act enters into force.
In vivo gene therapies not involving cell-processed products are newly regulated.
However, exosomes remain outside direct regulatory scope,
on the grounds that they are “not cells themselves.”
The “within two years” regulatory deadline referenced in the supplementary provision has arrived.
No specific regulatory proposal or legislative amendment has been publicly announced
by Japan’s MHLW as of June 2026.
Three Core Problems With Exosome Treatments as Currently Practiced
(Kyoto University group survey, published in international journal)
(IAPAM estimate)
(as of June 2026)
(as of June 2026)
Problem 1: Sold as “Research Reagents,” Injected as Treatments
Most exosome products circulating in Japan are classified and sold as “research-use reagents.”
Yet clinics are injecting these same products into patients.
This creates a persistent structural contradiction:
a product sold as a reagent is being used as a pharmaceutical.
Problem 2: No Quality, Purity, or Safety Standards
Products classified as reagents are not required to comply with
Good Manufacturing Practice (GMP) standards for pharmaceuticals.
There is no unified framework to verify exosome purity,
concentration, or the safety of other components in the formulation.
Problem 3: Patients Are Outside the Adverse Event Relief System
If a serious adverse event occurs at a clinic that has not filed the required notification
under the Regenerative Medicine Act,
the patient is likely ineligible for Japan’s national adverse drug reaction relief program.
The “elective cosmetic treatment” framing makes this situation even more complex.
Japan vs. the U.S.: How Regulators Diverge on Exosomes
⚖️ Japan (MHLW) vs. United States (FDA) — Regulatory Approaches to Exosomes
🇯🇵 Japan (MHLW)
“Not cells, therefore outside the Regenerative Medicine Act” —
exosome treatments continue as elective, out-of-pocket procedures.
Regulatory review is underway but no specific framework has been published.
Clinics are asked to follow society-issued guidance, not binding law.
🇺🇸 United States (FDA)
“Zero approved exosome products for cosmetic use.
Administering unapproved biologics to patients violates federal law.”
The FDA has issued warning letters to clinics offering exosome injections
and continues active enforcement.
What Patients Can Do Right Now
- “Has this exosome product been notified under the Regenerative Medicine Act?”
Ask whether the treatment requires — and has completed — the mandatory notification.
(Fully decellularized ECM proteins may be exempt, but confirmation is essential.) - “Can you provide documentation of the product’s ingredients, purity, and manufacturer?”
If the clinic cannot produce this, there is no quality assurance in place. - “What happens if I experience a serious side effect?”
Understand upfront whether you would be covered by any relief program —
or whether you are proceeding entirely at your own risk. - “Has the treating physician reviewed the Japanese Society for Regenerative Medicine’s
guidance on extracellular vesicle clinical applications?”
This is the guidance Japan’s MHLW has asked clinics to follow.
One year since enforcement. Whether regulations will actually move by 2026 as promised
remains publicly unconfirmed.
But regardless of what regulators do or don’t do,
the questions that matter for patients haven’t changed:
“What exactly is being injected? How is quality guaranteed?
And if something goes wrong — who is accountable?”
Patients have the right to ask all of these.
“Gray zone” does not mean “safe.”
It means “not yet regulated.”
Summary
- Even after Japan’s amended Regenerative Medicine Safety Act took effect on May 31, 2025,
exosomes remain outside its regulatory scope — classified as “not cells themselves.” - 669 clinics continue to offer exosome treatments nationwide,
with no mandatory quality standards and no patient relief system in place. - The U.S. FDA has declared zero approved exosome products for cosmetic use,
and administering them violates federal law —
a stark contrast to Japan’s current posture. - Japan’s MHLW had indicated regulations would arrive “by 2026,”
but no specific framework has been announced as of June 2026.
but they are also not approved as pharmaceuticals.
They exist in a regulatory gray zone: classified as “not cells,”
they fall outside the Regenerative Medicine Safety Act,
and no exosome formulation has received approval under Japan’s Pharmaceuticals and Medical Devices Act.
Clinics offer them as elective, out-of-pocket treatments.
not involving cell-processed products.
Exosomes were not brought under the law’s scope.
A supplementary provision had called for “legal measures within two years” —
but as of June 2026, no specific regulatory proposal has been published.
no exosome products are approved for cosmetic indications,
and administering unapproved biologics to patients violates federal law.
The agency has issued warning letters to clinics offering exosome injections.
Japan’s MHLW, by contrast, has not prohibited the practice
and continues to review a regulatory framework that has yet to be finalized.
Sources: Japan Ministry of Health, Labour and Welfare — “Act for Partial Amendment of the Act on the Safety of Regenerative Medicine, etc. and the Clinical Trials Act,” promulgated June 14, 2024, enforced May 31, 2025 / MHLW Pharmaceutical Affairs Bureau, Narcotics Control Department — “Monitoring and Guidance Regarding Exosome Reagents,” administrative notice dated July 31, 2024 / MHLW Medical Policy Bureau, Research and Development Policy Division — “Medical Practices Using Stem Cell Conditioned Media and Exosomes, etc.,” administrative notice dated July 31, 2024 / Japanese Society for Regenerative Medicine — “Guidance on Clinical Application of Extracellular Vesicles, etc.” / Nikkei Biotech — “MHLW Issues Caution as Exosome Product Sales Expand,” August 2024 / IAPAM — “Exosome Therapy in Aesthetic Practice: FDA Regulations 2026,” May 2026 / Hirotsunai Clinic — “Patient Death Following Stem Cell Administration: What Happened,” August 30, 2025
